Brad Margus, MBA
Brad Margus, MBA
Brad Margus currently leads Cerevance, a clinical-stage drug development company he co-founded to advance new therapeutics for brain diseases. The company has raised $94 million from GV (formerly Google Ventures), Bill Gates, Casdin Capital, Lightstone Ventures, Takeda Pharmaceuticals, Foresite Capital, UPMC Enterprises, Dolby Ventures and the Dementia Discovery Fund. In 2013, Mr. Margus started Genome Bridge, a non-profit subsidiary of the Broad Institute of Harvard and M.I.T., to build a computational platform for sharing genomic and clinical data.
From 2009 to 2012, as co-founder and CEO of Envoy Therapeutics, Mr. Margus led the discovery of new therapeutics for brain diseases and then sold the company to Takeda Pharmaceuticals. From 2000 to 2007, Mr. Margus was co-founder and CEO of Perlegen Sciences, a leader in analyzing genetic variation. Concurrent with his business career, for the last 25+ years, Mr. Margus has worked as a volunteer in founding and leading the A-T Children’s Project, a non-profit that orchestrates and funds research on a rare, brutal, genetic disease -- ataxia telangiectasia or "A-T" -- that two of his sons have. A-T causes progressive loss of muscle control, cancer and immune system problems. Mr. Margus currently serves on the Board of Arvinas (Nasdaq: ARVN), a protein degradation company; on the Board of Global Genes, a non-profit that supports advocates for all rare diseases; and as Co-chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the National Institutes of Health. Mr. Margus has previously served on the Advisory Council to the National Institute of Neurological Disorders and Stroke at the NIH; the Secretary of HHS's Advisory Committee on Genetics, Health and Society; the National Center for Advancing Translational Sciences Advisory Council; the Cure Acceleration Network Review Board; the Board of the Genetic Alliance, an umbrella organization representing hundreds of genetic disease advocacy organizations; as a Harvard Business School Global Advisor, as an advisor to Counsyl (acquired by Myriad Genetics); on the Board of Children’s Neurobiological Solutions; on the Board of Cellular Research, a molecular biology tool company (acquired by Becton Dickinson); on the Board of Second Genome, a microbiome company; and on the Stanford University School of Medicine’s Stem Cell Research Oversight Committee. Mr. Margus holds an MBA from Harvard Business School.